Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Oxytocin in obsessive compulsive disorder.

J A den Boer1, H G Westenberg

  • 1Department of Biological Psychiatry, Academical Hospital Utrecht, The Netherlands.

Peptides
|November 1, 1992
PubMed
Summary

This study found that intranasal oxytocin did not reduce obsessive-compulsive disorder (OCD) symptoms in patients. Higher doses also showed minimal effectiveness, suggesting oxytocin is not a viable anticompulsive treatment.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Ovariectomy-induced depressive-like behavior and brain glucose metabolism changes in female rats are not affected by chronic mild stress.

Psychoneuroendocrinology·2020
Same author

Serotonergic compounds in panic disorder, obsessive-compulsive disorder and anxious depression: A concise review.

Human psychopharmacology·2018
Same author

Considering depression as a consequence of activation of the inflammatory response system.

Acta neuropsychiatrica·2016
Same author

Biological concepts of anxiety disorders.

Acta neuropsychiatrica·2016
Same author

The flexible brain. On mind and brain, neural darwinism and psychiatry.

Acta neuropsychiatrica·2016
Same author

The role of the 'central' cholecystokinin-B receptor in panic disorder.

Acta neuropsychiatrica·2016

Area of Science:

  • Neuroscience
  • Psychiatry
  • Pharmacology

Background:

  • Obsessive-compulsive disorder (OCD) is a debilitating mental health condition.
  • Current treatments for OCD have limitations, prompting research into novel therapeutic agents.
  • Oxytocin, a neuropeptide, has been investigated for its potential role in social cognition and anxiety, suggesting possible effects on OCD.

Purpose of the Study:

  • To investigate the efficacy of intranasal oxytocin as a treatment for obsessive-compulsive disorder (OCD).
  • To determine if varying dosages of oxytocin influence its therapeutic effect on OCD symptoms.

Main Methods:

  • A double-blind, placebo-controlled study involving 12 patients diagnosed with OCD.
  • Patients received either intranasal oxytocin (18 IU/day) or a placebo.
  • An open-label extension with two additional patients explored a threefold higher oxytocin dosage.

Main Results:

  • No significant reduction in obsessions or compulsive behaviors was observed in the placebo-controlled phase.
  • The open-label phase showed a slight reduction in checking rituals in only one of two patients at a higher dose.
  • Overall, oxytocin administration did not demonstrate a clear therapeutic benefit for OCD symptoms.

Conclusions:

  • The findings do not support the use of oxytocin as an anticompulsive agent for OCD.
  • Further research may be needed to explore other mechanisms or patient subgroups, but current evidence is negative.
  • Oxytocin's role in treating OCD requires further investigation, but this study indicates limited potential.

Related Experiment Videos